Translational control of the fibroblast phenotype in IPF
Translational control of the fibroblast phenotype in IPF
批准号:
7680428
负责人:
Peter B Bitterman
金额:
$34.21万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2014-03-31
关键词:
AlveolarBindingBinding ProteinsBiologicalBiological MarkersBlood CirculationBreastCancer BiologyCell CycleCell ProliferationCell divisionCellsClinical TrialsDataDifferentiation and GrowthDiseaseEctodermElementsEpithelial CellsExcisionFibroblastsFrequenciesGene ExpressionGenesGenetically Engineered MouseGrowthGrowth FactorGrowth Factor ReceptorsHamman-Rich syndromeHumanInstructionIntegrinsKineticsLesionLinkLungMalignant NeoplasmsMalignant neoplasm of lungMapsMediatingMessenger RNAMicroRNAsMolecularMolecular AnalysisMolecular TargetNormal CellOncogenesOntologyOperonPathway interactionsPatientsPatternPhenotypePhysiologicalProcessProductionPropertyProteinsPublicationsRNARNA BindingRecruitment ActivityRefractoryRegulationRegulatory ElementReport (document)ReporterRibosomesRoleSamplingSignal TransductionSiteSourceSpecimenStructure of parenchyma of lungSystemSystems BiologyTestingTissuesTranscriptTranslatingTranslation InitiationTranslationsUntranslated RegionsZebrafishbasecancer cellepithelial to mesenchymal transitiongenome-wideinsightlung injurymorphogensprototyperesponsetheories
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Fibroblasts populating fibrotic lesions manifest an unexplained autonomy for growth and survival signals.
Fibrotic fibroblasts arise from at least 3 sources: the circulation, resident fibroblasts and the epithelial to
mesenchymal transition (EMT). However, the connection between fibroblast origin and autonomous function
remains undefined. Here we propose to study lung fibroblasts from patients with Idiopathic Pulmonary
Fibrosis and elucidate the mechanism of autonomous function using our discoveries in cancer biology as a
guide. In studies of human breast and lung cancer, we discovered that autonomy is conferred by
pathological regulation of the translation initiation machinery, designated elF4F. In cancer cells, elF4F
serves to integrate growth and survival signals from oncogenes by selectively recruiting ribosomes to groups
of transcripts that confer autonomy. Our preliminary data indicate that aberrant activation of elF4F is a
property of IFF fibroblasts; that activating elF4F in fibroblasts stimulates cell cycle entry in the absence of
growth factors; that mice genetically engineered to lack negative regulators of elF4F have an exaggerated
fibrotic response to lung injury; and that activating elF4F in zebrafish ectoderm explants triggers EMT. We
therefore hypothesize that pathological translational control contributes to the fibrotic phenotype in IPF by
mediating EMT and the emergence of proliferative autonomy. The framework for testing this hypothesis is
the post transcriptional operon theory, which posits that recruitment of ribosomes to mRNA is governed by
regulatory elements in the transcript 5' and 3' UTR. Acting alone or in concert with trans-acting protein or
micro RNA binding partners, RNA regulatory elements provide the instructions for ribosome recruitment. To
discover how these ribosome recruitment instructions might be altered in IPF, we propose 2 specific aims: 1)
Define the mechanisms linking pathological translational control with IPF fibroblast proliferative autonomy; 2)
Examine translational control of alveolar epithelial cell EMT and test its relevance to IPF. Our studies will
provide the first systems level, genome-wide examination of the fibrotic fibroblast phenotype based on a
quantitiative assesment of which mRNA are being actively translated into protein.
RELEVANCE (See instructions):
If successful, our studies will precisely identify derangements in the gene expression pathway that confer IPF
fibroblasts with a pathological phenotype and provide insight into the role of EMT in the genesis of fibroblasts
in the IPF lung.This information has the potential to reveal new classes of molecular targets for antifibrotic
therapy and unveil new disease-relevant biomarkers for clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of fibrotic extracellular matrix in generating the IPF Fibroblast
-
批准号:9187880
-
项目类别:
-
资助金额:$46.87万
-
财政年份:2014
-
负责人:Peter B Bitterman
-
依托单位:
Role of fibrotic extracellular matrix in generating the IPF Fibroblast
-
批准号:8794621
-
项目类别:
-
资助金额:$46.87万
-
财政年份:2014
-
负责人:Peter B Bitterman
-
依托单位:
Role of fibrotic extracellular matrix in generating the IPF Fibroblast
-
批准号:8982246
-
项目类别:
-
资助金额:$46.87万
-
财政年份:2014
-
负责人:Peter B Bitterman
-
依托单位:
Translational control of the fibroblast phenotype in IPF
-
批准号:8242756
-
项目类别:
-
资助金额:$47.79万
-
财政年份:2011
-
负责人:Peter B Bitterman
-
依托单位:
Translational Control in IPF
-
批准号:8119476
-
项目类别:
-
资助金额:$41.97万
-
财政年份:2008
-
负责人:Peter B Bitterman
-
依托单位:
Translational Control in IPF
-
批准号:7689897
-
项目类别:
-
资助金额:$44.57万
-
财政年份:2008
-
负责人:Peter B Bitterman
-
依托单位:
Translational Control in IPF
-
批准号:7899902
-
项目类别:
-
资助金额:$43.34万
-
财政年份:2008
-
负责人:Peter B Bitterman
-
依托单位:
Translational Control in IPF
-
批准号:7459477
-
项目类别:
-
资助金额:$45.8万
-
财政年份:2008
-
负责人:Peter B Bitterman
-
依托单位:
Summer Research at the University of Minnesota Medical School
-
批准号:8534803
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2007
-
负责人:Peter B Bitterman
-
依托单位:
Summer Research at the University of Minnesota Medical School
-
批准号:8680313
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2007
-
负责人:Peter B Bitterman
-
依托单位:
Translational State Assay for Human Samples
-
批准号:7343407
-
项目类别:
-
资助金额:$18.88万
-
财政年份:2007
-
负责人:Peter B Bitterman
-
依托单位:
Summer Research at the University of Minnesota Medical School
-
批准号:8366779
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2007
-
负责人:Peter B Bitterman
-
依托单位:
Summer Research at the University of Minnesota Medical School
-
批准号:8838851
-
项目类别:
-
资助金额:$15.75万
-
财政年份:2007
-
负责人:Peter B Bitterman
-
依托单位:
Translational State Assay for Human Samples
-
批准号:7741246
-
项目类别:
-
资助金额:$18.69万
-
财政年份:2007
-
负责人:Peter B Bitterman
-
依托单位:
Antifibrotic Drug Discovery in Acute Lung Injury
-
批准号:6879590
-
项目类别:
-
资助金额:$45.18万
-
财政年份:2004
-
负责人:Peter B Bitterman
-
依托单位:
Antifibrotic Drug Discovery in Acute Lung Injury
-
批准号:7036607
-
项目类别:
-
资助金额:$46.93万
-
财政年份:2004
-
负责人:Peter B Bitterman
-
依托单位:
Antifibrotic Drug Discovery in Acute Lung Injury
-
批准号:7189049
-
项目类别:
-
资助金额:$46.36万
-
财政年份:2004
-
负责人:Peter B Bitterman
-
依托单位:
Antifibrotic Drug Discovery in Acute Lung Injury
-
批准号:6760518
-
项目类别:
-
资助金额:$44.98万
-
财政年份:2004
-
负责人:Peter B Bitterman
-
依托单位:
Molecular Targets for Drug Discovery in IPF
-
批准号:6794765
-
项目类别:
-
资助金额:$74.25万
-
财政年份:2003
-
负责人:Peter B Bitterman
-
依托单位:
Molecular Targets for Drug Discovery in IPF
-
批准号:6663549
-
项目类别:
-
资助金额:$74.08万
-
财政年份:2003
-
负责人:Peter B Bitterman
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: